Loading
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Previous close
$5.39
+$0.12 · +2.28%
Regular session · ET · Market data may be delayed.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Day range
Current $5.39
52-week range
Current $5.39
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
42
Mixed
Risk
54
Elevated Risk
Momentum
81
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Day range
Current $5.39
52-week range
Current $5.39
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 1.72M USD | 1.12M USD |
| Gross profit | — | — | — | −1.72M USD | −1.12M USD |
| Research and development | 23.81M USD | 22.81M USD | 16.15M USD | 27.99M USD | 30.42M USD |
| Selling, general, and administrative | 9.16M USD | 5.22M USD | 6.72M USD | 10.9M USD | 12.45M USD |
| Operating expenses | 32.97M USD | 28.03M USD | 22.87M USD | 37.17M USD | 42.03M USD |
| Interest income | — | 442K USD | 548K USD | 267K USD | 468K USD |
| Interest expense | 685K USD | 1.53M USD | 1.71M USD | 1.34M USD | — |
| Depreciation and amortization | 1.62M USD | 1.62M USD | 1.82M USD | 1.72M USD | 1.12M USD |
| Operating income | −32.97M USD | −28.03M USD | −22.87M USD | −38.89M USD | −43.15M USD |
| Net income | −34.17M USD | −29.02M USD | −23.87M USD | −39.53M USD | −40.71M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.50
131.91% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 21, 2023 | 1:30 | — | — |
Effective Sep 21, 2023
1:30
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
